The patent eligibility of human embryonic stem cell technology in Europe

Aktivitet: Tale eller præsentation - typerForedrag og mundtlige bidrag

Timo Minssen - Foredragsholder

On 18 October, 2011 the CJEU rendered its keenly-awaited decision in Brüstle v Greenpeace. Interpreting key -provisions of the EU Biotech Directive, the Court held that a process which involves removal of a stem cell from a human embryo at the blastocyst stage, entailing the destruction of that embryo, cannot be patented. This presentation will analyse the context, outcome & implications of this seminal judgment, which complements the EPO’s WARF decision and which has now also been reflected in the EPO’s new examination guidelines (June 2012). If time allows, short references will be made to the current US law on this issue.

A presentation given at a 5 days intensive training for practitioners/professionals in Pharma Law & Policy (CSU), 13 – 17 August 2012, 9, at the University of Copenhagen, Frederiksberg Campus
13 aug. 2012

Begivenhed (Kursus)

TitelPharmaceutical Law & Policy- Hot topics shaping the future of the pharma industry
Forkortet titelCSU
AfholdelsesstedUniversity of Copenhagen, Frederiksberg Campus

ID: 40312495